Bempedoic Acid Pregnancy Surveillance Program FDA Decision: Century Therapeutics, Inc. (IPSC)

The Clinical Trial date for Bempedoic Acid Pregnancy Surveillance Program by Century Therapeutics, Inc. (IPSC) is scheduled for May 1, 2032. This is the target date for the FDA to make a decision on this application.

Bempedoic Acid Pregnancy Surveillance Program is being developed by Century Therapeutics, Inc. for the treatment of its target indication. It is currently in Clinical Trial clinical trials.

If Bempedoic Acid Pregnancy Surveillance Program receives FDA approval, Century Therapeutics, Inc. (IPSC) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Clinical Trial date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for IPSC on DilutionWatch at dilutionwatch.com/stock/IPSC.html.

You can view the full BiotechSigns company profile for Century Therapeutics, Inc. (IPSC) at biotechsign.com/app/company/IPSC, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.